The Role of Tumor Mutational Burden in Lung Cancer

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.

Related Videos

October 14, 2014

Useful Patient Tools Available for Patients with Polycythemia Vera

Dr. Michaelis discusses useful tools in her experience for treatment of polycthemia vera.Supported through funding from Incyte

January 13, 2015

When to Use Breast Cancer Index

Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss the circumstances in which they would use the Breast Cancer IndexSM (BCI) to assist in determining whether to extend the adjuvant therapy of women with breast cancer beyond 5 years.